title: Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics.
abstract: Protein stability remains one of the main factors limiting the realization of the full potential of protein therapeutics. Poly(ethylene glycol) (PEG) conjugation to proteins has evolved into an important tool to overcome instability issues associated with proteins. The observed increase in thermodynamic stability of several proteins upon PEGylation has been hypothesized to arise from reduced protein structural dynamics, although experimental evidence for this hypothesis is currently missing. To test this hypothesis, the model protein alpha-chymotrypsin (alpha-CT) was covalently modified with PEGs with molecular weights (M(W)) of 700, 2,000 and 5,000 and the degree of modification was systematically varied. The procedure did not cause significant tertiary structure changes. Thermodynamic unfolding experiments revealed that PEGylation increased the thermal transition temperature (T(m)) of alpha-CT by up to 6 degrees C and the free energy of unfolding [DeltaG(U) (25 degrees C)] by up to 5 kcal/mol. The increase in stability was found to be independent of the PEG M(W) and it leveled off after an average of four PEG molecules were bound to alpha-CT. Fourier-transformed infrared (FTIR) H/D exchange experiments were conducted to characterize the conformational dynamics of the PEG-conjugates. It was found that the magnitude of thermodynamic stabilization correlates with a reduction in protein structural dynamics and was independent of the PEG M(W). Thus, the initial hypothesis proved positive. Similar to the thermodynamic stabilization of proteins by covalent modification with glycans, PEG thermodynamically stabilizes alpha-CT by reducing protein structural dynamics. These results provide guidance for the future development of stable protein formulations.
authors.affiliation: Department of Chemistry, University of Puerto Rico-Río Piedras, San Juan, Puerto Rico.
authors.forename: José A
authors.initials: JA
authors.lastname: Rodríguez-Martínez
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Solá
authors.forename: Betzaida
authors.initials: B
authors.lastname: Castillo
authors.forename: Héctor R
authors.initials: HR
authors.lastname: Cintrón-Colón
authors.forename: Izarys
authors.initials: I
authors.lastname: Rivera-Rivera
authors.forename: Gabriel
authors.initials: G
authors.lastname: Barletta
authors.forename: Kai
authors.initials: K
authors.lastname: Griebenow
mesh_terms: D002918:Chymotrypsin / Q000737:chemistry* / Q000378:metabolism; D002942:Circular Dichroism; D004795:Enzyme Stability; D005583:Fourier Analysis; D011092:Polyethylene Glycols / Q000378:metabolism; D017434:Protein Structure, Tertiary; D013696:Temperature
chemical_list: D011092:Polyethylene Glycols; D002918:Chymotrypsin; C117608:alpha-chymotrypsin
references.citation: Arch Biochem Biophys. 1996 Sep 1;333(1):75-84
references.pmid: 8806756
references.citation: Cell Mol Life Sci. 2007 Aug;64(16):2133-52
references.pmid: 17558468
references.citation: J Biol Chem. 1977 Jun 10;252(11):3582-6
references.pmid: 16907
references.citation: J Pharm Sci. 2005 Feb;94(2):327-40
references.pmid: 15570602
references.citation: Bioconjug Chem. 2002 Nov-Dec;13(6):1336-44
references.pmid: 12440871
references.citation: Adv Protein Chem. 1966;21:287-386
references.pmid: 5333290
references.citation: Anal Biochem. 1966 Mar;14(3):328-36
references.pmid: 4161471
references.citation: Bioconjug Chem. 2006 Jul-Aug;17(4):995-9
references.pmid: 16848407
references.citation: Protein Sci. 2003 Jul;12(7):1496-506
references.pmid: 12824495
references.citation: Biochemistry. 1995 Jan 10;34(1):172-9
references.pmid: 7819193
references.citation: Bioconjug Chem. 2006 May-Jun;17(3):618-30
references.pmid: 16704199
references.citation: J Pharm Pharmacol. 2002 Mar;54(3):301-13
references.pmid: 11902796
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7406-11
references.pmid: 9636162
references.citation: J Biol Chem. 1977 Jun 10;252(11):3578-81
references.pmid: 405385
references.citation: Biotechnol Bioeng. 2008 Jan 1;99(1):9-17
references.pmid: 17546684
references.citation: Int J Pharm. 2002 Apr 26;237(1-2):163-70
references.pmid: 11955814
references.citation: Biochemistry. 2002 Dec 17;41(50):14771-8
references.pmid: 12475225
references.citation: Bioconjug Chem. 2003 Mar-Apr;14(2):464-72
references.pmid: 12643758
references.citation: Pharm Res. 1989 Nov;6(11):903-18
references.pmid: 2687836
references.citation: Drug Discov Today. 2005 Nov 1;10(21):1451-8
references.pmid: 16243265
references.citation: Nat Rev Drug Discov. 2005 Apr;4(4):298-306
references.pmid: 15803194
references.citation: Biotechnol Bioeng. 2006 Aug 20;94(6):1072-9
references.pmid: 16586505
references.citation: Nature. 1979 Aug 23;280(5724):693-6
references.pmid: 224319
references.citation: Biotechnol Bioeng. 2006 Jun 20;94(3):565-74
references.pmid: 16496401
references.citation: Biophys J. 2008 Jan 1;94(1):173-81
references.pmid: 17827244
references.citation: FEBS Lett. 2006 Mar 6;580(6):1685-90
references.pmid: 16494868
references.citation: FEBS J. 2006 Dec;273(23):5303-19
references.pmid: 17076704
references.citation: Int J Pharm. 1999 Aug 20;185(2):129-88
references.pmid: 10460913
references.citation: Nat Rev Drug Discov. 2003 Mar;2(3):214-21
references.pmid: 12612647
references.citation: AAPS J. 2006 Sep 15;8(3):E572-9
references.pmid: 17025275
references.citation: Bioconjug Chem. 2006 Jul-Aug;17(4):1093-8
references.pmid: 16848420
references.citation: Trends Biotechnol. 1990 Apr;8(4):93-8
references.pmid: 1367432
references.citation: Biochemistry. 2004 Jan 27;43(3):587-94
references.pmid: 14730962
references.citation: Int J Pharm. 2000 Aug 10;203(1-2):1-60
references.pmid: 10967427
references.citation: Bioconjug Chem. 1995 Jul-Aug;6(4):380-8
references.pmid: 7578357